jhavlek

About Jennifer Havlek

This author has not yet filled in any details.
So far Jennifer Havlek has created 60 blog entries.
21 Nov, 2022

2022 SITC Poster #146: Transcriptome augmentation provides accurate and sensitive quantification of genes associated with the tumor microenvironment

2022 AACR Poster #146: Transcriptome augmentation provides accurate and sensitive quantification of genes associated with the tumor microenvironment Overview Tumors harbor a complex and dynamic ecosystem of malignant, immune, and stromal cells. While malignant cells dictate much of the tumor biology, there is evidence that the tumor microenvironment (TME) also plays a significant role [...]

21 Nov, 2022

2022 SITC Poster #51: A combination of antigen presentation and T-cell recognition features improves neoantigen immunogenicity predictions

2022 SITC Poster #51: A combination of antigen presentation and T-cell recognition features improves neoantigen immunogenicity predictions Overview Tumor neoantigen burden outperforms tumor mutational burden (TMB) in prediction of patient response to immune checkpoint blockade (ICB) therapy by better capturing the biological mechanism underlying response [1]. However, immune recognition of neoantigens by T-cells requires [...]

21 Nov, 2022

2022 SITC Poster #119: Sensitive prediction of immunotherapy response by integrating immune infiltration and neoantigen presentation score in late-stage melanoma

2022 SITC Poster #119: Sensitive prediction of immunotherapy response by integrating immune infiltration and neoantigen presentation score in late-stage melanoma Overview Single-modality biomarkers such as tumor mutational burden (TMB) often fail to reliably predict response to immune checkpoint blockade (ICB), likely due to incomplete characterization of the complex tumor-immune interactions that influence treatment efficacy. We [...]

22 May, 2021

2021 AACR: Personalis Product Demo

2021 AACR Personalis Product Demo Advancing Biomarker Discovery: Enabling improved tumor immunogenomics through a comprehensive approach Travis Yates, PhD Field Applications Scientist This presentation will cover: Predicting patient response to immunotherapies requires a robust and comprehensive approach to tumor immunogenomics. By combining highly [...]

3 May, 2021

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology January 2021  O'Hara, Mark H et al. View Publication

3 May, 2021

Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients.

Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients. Journal for ImmunoTherapy of Cancer  November 2020 Feng Z, Scheuenpflug J, Tan M et al. View Publication View PDF

Go to Top